UK pension funds vie to lead court action over GSK drug

I wonder if JP Garnier has seen the Times this morning?

Two UK pension funds are vying to lead a US class action lawsuit against GlaxoSmithKline (GSK), accusing the pharmaceutical giant of misleading the market over its controversial diabetes pill Avandia.

North Yorkshire Pension Fund and Avon Pension Fund, local government schemes that together manage more than £3 billion in assets, have both applied to be lead plaintiff in the case – a US term for the institution fronting a lawsuit on behalf of other investors.

While UK funds frequently join US class action lawsuits as minor players, it is highly unusual for them to seek such a prominent role. The funds have jointly appointed Coughlin, Stoia, Geller, Rudman and Robbins, a New York law firm, to represent them.

The two UK funds are understood to be claiming they suffered losses of roughly $5 million as a result. “We are joining [the lawsuit] because it is in our members’ interests to do so,” Neil Sellström from the North Yorkshire fund said.

“We monitor class actions and when one is launched against a company where we hold or have held the shares, we assess its merits and get involved where we think it is appropriate.”

Avon confirmed its involvement in the lawsuit but declined further comment. A German and a US group are also seeking to act as lead plaintiff.

A judge is expected to make a final decision on which group to pick next week. Both UK funds have indicated they will remain involved in the case in a lesser role regardless. The lawsuit, originally filed in New York on June 11 by the law firm Kaplan Fox, alleges that GSK “engaged in a scheme to deceive the market and a course of conduct that artificially inflated GSK’s stock price”. It claims that GSK “failed to adequately disclose” important information about the risks of the drug and accuses the company of “fraud” and “deceit”.

Full story here.

3 Responses to “UK pension funds vie to lead court action over GSK drug”

  1. Matthew Holford Says:

    There must be something in the Listing Rules about this kind of thing… I’m off to do a bit of reading.

    Matt

  2. Matthew Holford Says:

    Hmmm. Very broad: there’s a bunch of stuff in there that you’d need to research, before you could work out if it was any use. Stuff about audit committees, independent directors, promoting ethical behaviour, and whatnot:

    http://www.nyse.com/pdfs/finalcorpgovrules.pdf

    Matt

  3. truthman30 Says:

    “engaged in a scheme to deceive the market and a course of conduct that artificially inflated GSK’s stock price”. It claims that GSK “failed to adequately disclose” important information about the risks of the drug and accuses the company of “fraud” and “deceit”.

    Interesting…
    Because The words “Fraud” and “deceit” seem to be synonomous with almost every article printed about GSK in the last 6 years ….


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: